In Canada, cannabis use has risen to new levels during the COVID-19 pandemic, even among people who never consumed it before.
According to the most recent Statistics Canada figures, Toronto led the country in sales in January 2021 at $31 million.
Toronto started 2020 with only 7 cannabis stores serving the city’s entire legal market and gradually rising through the year, ending the year with over 85 cannabis stores and could grow further as FUNN Dispensaries, Inc. has been approved for incorporation in Canada.
Early this year, Amfil Technologies Inc. (OTC US: FUNN) announced progress with its plans to expand into the Canadian green market and the projected timeline for the opening of the first dispensary is approximately 3 months.
On August 31, 2020, Tokin Dispensaries Inc. and David Berkovits entered into an assignment agreement with FUNN whereby Tokin assigned assets to FUNN. Tokin was and is a licensed cannabis retail operator in Ontario. Tokin initially secured a lease for one dispensary location at 10 Dunlop Drive, St. Catharines in the Greater Toronto area. All rights and responsibilities regarding that location were assigned to FUNN through the assignment agreement. FUNN also has space for a suitable location near one of the Snakes & Lattes venues in Toronto. Berkovits has additional locations to be considered, and has taken responsibility for obtaining dispensary licenses for FUNN in existing and future locations.
The current status of materializing this agreement is as follows:
- FUNN Dispensaries, Inc. has been approved for incorporation in Canada. Federal Corporation Information – 1264130-5 – Online Filing Centre – Corporations Canada – Corporations – Innovation, Science and Economic Development Canada. Amfil Technologies Inc. owns 100% of this corporation.
- FUNN Dispensaries, Inc. has begun the process of acquiring the necessary dispensary operator’s license.
- FUNN Dispensaries, Inc. has signed an agreement with the landlord to immediately take over the lease for 10 Dunlop.
- Bids have already been approved and contractors have been hired to build out the first location at 10 Dunlop.
- Funds have been appropriated for FUNN Dispensaries, Inc. to complete the buildout.
- Projected timeline to open the first location is approximately 3 months pending buildout and transfer of the operator’s license and location permit. A firm opening date will be announced at the appropriate time.
The Company’s new cannabis dispensary division will be led by experienced and licensed cannabis dispensary operator, David Berkovits.
Amfil’s current plan is to scale this business through additional locations in Toronto and beyond. As the cannabis industry continues to thrive in Canada, Success of this new business model could add significant value to the company.
High Tide Inc. (NASDAQ: HITI), a retail-focused cannabis corporation enhanced by the manufacturing and distribution of consumption accessories, recently acquired Canna Cabana retail cannabis store located at 435(B) Yonge Street in Toronto, Ontario. being one of the original 25 cannabis retail stores operating in the province.
The Company is the most profitable Canadian retailer of recreational cannabis with 85 current locations in Ontario, Alberta, Manitoba, and Saskatchewan.
The company has additional locations under development across the country.
High Tide is the first major publicly traded cannabis retailer to begin trading on the Nasdaq exchange.
As the cannabis sector remains one of the best place for investors seeking big profits, Amfil Technologies Inc. (OTC US: FUNN) and High Tide Inc. (NASDAQ: HITI) should be highly considered at current levels.
DISCLAIMER: EDM Media LLC (EDM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. EDM is NOT affiliated in any manner with any company mentioned herein. EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. EDM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. EDM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed EDM has been compensated fifteen thousand dollars for news coverage of the current press releases issued by Amfil Technologies Inc. (OTC US: FUNN) by the company.
EDM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.
EDM Media LLC
Coinsmart. Beste Bitcoin-Börse in Europa
Uncovering the mysteries of milk
Sarah Nyquist got her first introduction to biology during high school, when she took an online MIT course taught by genomics pioneer Eric Lander. Initially unsure what to expect, she quickly discovered biology to be her favorite subject. She began experimenting with anything she could find, beginning with an old PCR machine and some dining hall vegetables.
Nyquist entered college as a biology major but soon gravitated toward the more hands-on style of the coursework in her computer science classes. Even as a computer science major and a two-time summer intern at Google, biology was never far from Nyquist’s mind. Her favorite class was taught by a computational biology professor: “It got me so excited to use computer science as a tool to interrogate biological questions,” she recalls.
During her last two years as an undergraduate at Rice University, Nyquist also worked in a lab at Baylor College of Medicine, eventually co-authoring a paper with Eric Lander himself.
Nyquist is now a PhD candidate studying computational and systems biology. Her work is co-advised by professors Alex Shalek and Bonnie Berger and uses machine learning to understand single-cell genomic data. Since this technology can be applied to nearly any living material, Nyquist was left to choose her focus.
After shifting between potential thesis ideas, Nyquist finally settled on studying lactation, an important and overlooked topic in human development. She and postdoc Brittany Goods are currently part of the MIT Milk Study, the first longitudinal study to profile the cells in human breast milk using single cell genomic data. “A lot of people don’t realize there’s actually live cells in breast milk. Our research is to see what the different cell types are and what they might be doing,” Nyquist says.
While she started out at MIT studying infectious diseases, Nyquist now enjoys investigating basic science questions about the reproductive health of people assigned female at birth. “Working on my dissertation has opened my eyes to this really important area of research. As a woman, I’ve always noticed a lot is unknown about female reproductive health,” she says. “The idea that I can contribute to that knowledge is really exciting to me.”
The complexities of milk
For her thesis, Nyquist and her team have sourced breast milk from over a dozen donors. These samples are provided immediately postpartum to around 40 weeks later, which provides insight into how breast milk changes over time. “We took record of the many changing environmental factors, such as if the child had started day care, if the mother had started menstruating, or if the mother had started hormonal birth control,” says Nyquist. “Any of these co-factors could explain the compositional changes we witnessed.”
Nyquist also hypothesized that discoveries about breast milk could be a proxy for studying breast tissue. Since breast tissue is necessary for lactation, researchers have been historically struggled to collect tissue samples. “A lot is unknown about the cellular composition of human breast tissue during lactation, even though it produces an important early source of nutrition,” she adds.
Overall, the team has found a lot of heterogeneity between donors, suggesting breast milk is more complicated than expected. They have witnessed that the cells in milk are composed primarily of a type of structural cells that increase in quantity over time. Her team hypothesized that this transformation could be due to the high turnover of breast epithelial tissue during breastfeeding. While the reasons are still unclear, their data add to the field’s previous understandings.
Other aspects of their findings have validated some early discoveries about important immune cells in breast milk. “We found a type of macrophage in human breast milk that other researchers have identified before in mouse breast tissue,” says Nyquist. “We were really excited that our results confirmed similar things they were seeing.”
Applying her research to Covid-19
In addition to studying cells in breast milk, Nyquist has applied her skills to studying organ cells that can be infected by Covid-19. The study began early into the pandemic, when Nyquist and her lab mates realized they could explore their lab’s collective cellular data in a new way. “We began looking to see if there were any cells that expressed genes that can be hijacked for cellular entry by the Covid-19 virus,” she says. “Sure enough, we found there are cells in nasal, lung, and gut tissues that are more susceptible to mediating viral entry.”
Their results were published and communicated to the public at a rapid speed. To Nyquist, this was evidence for how collaboration and computational tools are essential at producing next generation biological research. “I had never been on a project this fast-moving before — we were able to produce figures in just two weeks. I think it was encouraging to the public to see that scientists are working on this so quickly,” she says.
Outside of her own research, Nyquist enjoys mentoring and teaching other scientists. One of her favorite experiences was teaching coding at HSSP, a multiweekend program for middle and high schoolers, run by MIT students. The experience encouraged her to think of ways to make coding approachable to students of any background. “It can be challenging to figure out whether to message it as easy or hard, because either can scare people away. I try to get people excited enough to where they can learn the basics and build confidence to dive in further,” she says.
After graduation, Nyquist hopes to continue her love for mentoring by pursuing a career as a professor. She plans on deepening her research into uterine health, potentially by studying how different infectious diseases affect female reproductive tissues. Her goal is to provide greater insight about biological processes that have long been considered taboo.
“It’s crazy to me that we have so much more to learn about important topics like periods, breastfeeding, or menopause,” says Nyquist. “For example, we don’t understand how some medications impact people differently during pregnancy. Some doctors tell pregnant people to go off their antidepressants, because they worry it might affect their baby. In reality, there’s so much we don’t actually know.”
“When I tell people that this is my career direction, they often say that it’s hard to get funding for female reproductive health research, since it only affects 50 percent of the population,” she says.
“I think I can convince them to change their minds.”
Queen of hearts
Amphibians and humans differ in many ways, but Laurie Boyer, a professor of biology and biological engineering at MIT, is particularly interested in one of those differences. Certain types of amphibians and fish can regenerate and heal their hearts after an injury. In contrast, human adults who have experienced trauma to the heart, such as in the case of a heart attack or exposure to certain medications, are unable to repair the damage. Often, the injured heart ends up with scar tissue that can lead to heart failure.
Recent research in this area now indicates that mice, and even humans, have some capacity for cardiac repair for a short period after birth. But after even just a few days of age, that ability starts to shut off. “The heart has very limited ability to repair itself in response to injury, disease, or aging,” Boyer says.
Alexander Auld, a postdoc in the Boyer Lab, studies the key cellular mechanisms that lead heart cells to mature and lose regenerative potential. Specifically, he’s interested in understanding how cardiomyocytes, the heart cells responsible for pumping blood, develop an ability to contract and relax repeatedly. Auld tests the function of proteins that serve as signals to assemble the cardiac muscle structure after birth. The assembly of these structures coincides with the loss of regenerative ability.
“I’m trying to piece together: What are the different mechanisms that push cardiomyocytes to assemble their contractile apparatus and to stop dividing?” Auld says. “Solving this puzzle may have potential to stimulate regeneration in the adult heart muscle.”
“The holy grail of regenerative biology would be to stimulate your own heart cells to replenish themselves,” says Boyer, who joined the MIT faculty in 2007. “Before this approach is possible, we need to achieve a deep understanding of the fundamental processes that drive heart development.”
Boyer’s lab studies how many different signals and genes interact to affect heart development. The work will enable a better understanding of how faulty regulation can lead to disease, and may also enable new therapies for people suffering from a variety of heart conditions.
Recently, Boyer’s lab has been studying heart development in people with Trisomy 21, or Down syndrome. Every year, 6,000 babies born in the United States have Down syndrome. Around half have heart defects. The most common heart defect in babies with Down syndrome is a hole in the heart’s center, called an atrioventricular septal defect. It is often repaired with surgery, but the repair can cause scar tissue and cardiovascular complications.
Somatic cells are those that compose an organism’s body; they differ from sex cells, which are used for reproduction. Most people have 46 chromosomes, arranged in 23 pairs, in their body’s somatic cells. In 95 percent of cases, Down syndrome results when a person has three copies of chromosome 21 instead of two –– a total of 47 chromosomes per cell. It’s an example of aneuploidy, when a cell has an abnormal number of chromosomes. Cellular attempts to adapt to the extra chromosome can cause stress on the body’s cells, including those of the heart.
MIT’s Alana Down Syndrome Center (ADSC) brings together biologists, neuroscientists, engineers, and other experts to increase knowledge about Down syndrome. ADSC launched in early 2019, led by Angelika Amon, professor of biology and a member of the Koch Institute for Integrative Cancer Research, along with co-director Li-Huei Tsai, Picower Professor and director of the Picower Institute for Learning and Memory. Amon died at age 53 in 2020 after a battle with ovarian cancer. At MIT, Amon had studied the effects of aneuploidy on cells.
“In my many wonderful scientific and personal discussions with Angelika, who was a beacon of inspiration to me, it became clear that studying Trisomy 21 in the context of heart development could ultimately improve the lives of these individuals,” Boyer says.
Change of heart
To conduct their research, Boyer’s group uses human induced pluripotent cells (hiPSCs), obtained through somatic cell reprogramming. The revolutionary technique was developed by Sir John B. Gurdon and Shinya Yamanaka, who in 2012 won the Nobel Prize in Physiology or Medicine for their work. Reprogramming works by converting specialized, mature somatic cells with one particular function into specialized, mature, cells with a different function.
Boyer’s lab uses hiPSCs from human adults with Down syndrome and converts them into cardiomyocytes through somatic cell reprogramming. Then, they compare those cardiomyocytes with reprogrammed cells from individuals who do not have Down syndrome. This work helps them deduce why the extra chromosome in people with Down syndrome may cause congenital heart defects.
“We can now begin to pinpoint the faulty signals and genes in Trisomy 21 cardiac cells that affect heart development,” Boyer says. “And with that same idea, we can also discover how we might actually be able to ameliorate or fix these defects.”
With this technique, the team can track how aspects of a specific patient’s cell development correlate with their clinical presentation. The ability to analyze patient-specific cells also has implications for personalized medicine, Boyer says. For instance, a patient’s skin or blood cells –– which are more easily obtained –– could be converted into a highly specialized mature cell, like a cardiac muscle cell, and tested for its response to drugs that could possibly cause damage to the heart before they reach the clinic. This process can also be used to screen for new therapies that can improve the outcome for heart failure patients.
Boyer presented the group’s research on Down syndrome at the New England Down Syndrome Symposium, co-organized in November 2020 by MIT, ADSC, Massachusetts Down Syndrome Congress, and LuMind IDSC Foundation.
Heart of the operation
Boyer’s lab employs students at the undergraduate, graduate, and postdoc levels from engineering, life sciences, and computer sciences –– each of whom, Boyer says, brings unique expertise and value to the team.
“It’s important for me to have a lab where everyone feels welcome, and that they feel that they can contribute to these fundamental discoveries,” Boyer says.
The Boyer Lab often works with scholars across disciplines at MIT. “It’s really great,” Auld says. “You can investigate a problem using multiple tools and perspectives.”
One project, in partnership with George Barbastathis, a professor in mechanical engineering, uses image-based machine learning to understand structural differences within cardiomyocytes when the proteins that signal cells to develop have been manipulated. Auld generates high-resolution images that the machine learning algorithms can analyze.
Another project, in collaboration with Ed Boyden, a professor in the Department of Biological Engineering as well as the McGovern Institute for Brain Research, involves the development of new technologies that allow high-throughput imaging of cardiac cells. The cross-pollination across departments and areas of expertise at MIT, Boyer says, often has her feeling like “a kid in a candy shop.”
“That our work could ultimately impact human health is very fulfilling for me, and the ability to use our scientific discoveries to improve medical outcomes is an important direction of my lab,” Boyer says. “Given the enormous talent at MIT and the excitement and willingness of everyone here to work together, we have an unprecedented opportunity to solve important problems that can make a difference in people’s lives.”
USC Stem Cell scientists make big progress in building mini-kidneys
The organoids, which resemble a kidney’s uretic buds, provide a way to study kidney disease that could lead to new treatments and regenerative approaches for patients
A team of scientists at the Keck School of Medicine of USC has created what could be a key building block for assembling a synthetic kidney. In a new study in Nature Communications, Zhongwei Li and his colleagues describe how they can generate rudimentary kidney structures, known as organoids, that resemble the collecting duct system that helps maintain the body’s fluid and pH balance by concentrating and transporting urine.
“Our progress in creating new types of kidney organoids provides powerful tools for not only understanding development and disease, but also finding new treatments and regenerative approaches for patients,” said Li, the study’s corresponding author and an assistant professor of medicine, and of stem cell biology and regenerative medicine.
Creating the building blocks
The first authors of the study, PhD student Zipeng Zeng and postdoc Biao Huang, and the team started with a population of what are known as ureteric bud progenitor cells, or UPCs, that play an important role in early kidney development. Using first mouse and then human UPCs, the scientists were able to develop cocktails of molecules that encourage the cells to form organoids resembling uretic buds–the branching tubes that eventually give rise to the collecting duct system. The scientists also succeeded in finding a different cocktail to induce human stem cells to develop into ureteric bud organoids.
An additional molecular cocktail pushed ureteric bud organoids–grown from either mouse UPCs or human stem cells–to reliably develop into even more mature and complex collecting duct organoids.
The human and mouse ureteric bud organoids can also be genetically engineered to harbor mutations that cause disease in patients, providing better models for understanding kidney problems, as well as for screening potential therapeutic drugs. As one example, the scientists knocked out a gene to create an organoid model of congenital anomalies of the kidney and urinary tract, known as CAKUT.
In addition to serving as models of disease, ureteric bud organoids could also prove to be an essential ingredient in the recipe for a synthetic kidney. To explore this possibility, the scientists combined mouse ureteric bud organoids with a second population of mouse cells: the progenitor cells that form nephrons, which are the filtering units of the kidney. After inserting the tip of a lab-grown ureteric bud into a clump of NPCs, the team observed the growth of an extensive network of branching tubes reminiscent of a collecting duct system, fused with rudimentary nephrons.
“Our engineered mouse kidney established a connection between nephron and collecting duct–an essential milestone towards building a functional organ in the future,” said Li.
About the Study
The project brought together scientists from the USC/UKRO Kidney Research Center, Li’s primary affiliation; the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC; the departments of Medicine, and Stem Cell Biology and Regenerative Medicine; and the divisions of Nephrology and Hypertension, and Maternal Fetal Medicine. Additional authors include Riana K. Parvez, Yidan Li, Jyunhao Chen, Ariel C. Vonk, Matthew E. Thornton, Tadrushi Patel, Elisabeth A. Rutledge, Albert D. Kim, Jingying Yu, Brendan H. Grubbs, Jill A. McMahon, Núria M. Pastor-Soler, Kenneth R. Hallows and Andrew P. McMahon.
Twenty percent of this work was supported by federal funding from the National Institute of Diabetes and Digestive and Kidney Diseases (grant DK054364 and F31 fellowship DK107216). The remainder of the support came from departmental startup funding, UKRO foundation support, a USC Stem Cell Challenge Award, and the California Institute for Regenerative Medicine (CIRM) Bridges Program.
About Keck School of Medicine
Founded in 1885, the Keck School of Medicine of USC is one of the nation’s leading medical institutions, known for innovative patient care, scientific discovery, education, and community service. Medical and graduate students work closely with world-renowned faculty and receive hands-on training in one of the nation’s most diverse communities. They participate in cutting-edge research as they develop into tomorrow’s health leaders. With more than 900 resident physicians across 50 specialty and subspecialty programs, the Keck School is the largest educator of physicians practicing in Southern California.
New AI model helps understand virus spread from animals to humans
A new model that applies artificial intelligence to carbohydrates improves the understanding of the infection process and could help predict which viruses are likely to spread from animals to humans. This is reported in a recent study led by researchers at the University of Gothenburg.
Carbohydrates participate in nearly all biological processes – yet they are still not well understood. Referred to as glycans, these carbohydrates are crucial to making our body work the way it is supposed to. However, with a frightening frequency, they are also involved when our body does not work as intended. Nearly all viruses use glycans as their first contact with our cells in the process of infection, including our current menace SARS-CoV-2, causing the COVID-19 pandemic.
A research group led by Daniel Bojar, assistant professor at the University of Gothenburg, has now developed an artificial intelligence-based model to analyze glycans with an unprecedented level of accuracy. The model improves the understanding of the infection process by making it possible to predict new virus-glycan interactions, for example between glycans and influenza viruses or rotaviruses: a common cause for viral infections in infants.
As a result, the model can also lead to a better understanding of zoonotic diseases, where viruses spread from animals to humans.
“With the emergence of SARS-CoV-2, we have seen the potentially devastating consequences of viruses jumping from animals to humans. Our model can now be used to predict which viruses are particularly close to “jumping over”. We can analyze this by seeing how many mutations would be necessary for the viruses to recognize human glycans, which increases the risk of human infection. Also, the model helps us predict which parts of the human body are likely targeted by a potentially zoonotic virus, such as the respiratory system or the gastrointestinal tract”, says Daniel Bojar, who is the main author of the study.
In addition, the research group hopes to leverage the improved understanding of the infection process to prevent viral infection. The aim is to use the model to develop glycan-based antivirals, medicines that suppress the ability of viruses to replicate.
“Predicting virus-glycan interactions means we can now search for glycans that bind viruses better than our own glycans do, and use these “decoy” glycans as antivirals to prevent viral infection. However, further advances in glycan manufacturing are necessary, as potential antiviral glycans might include diverse sequences that are currently difficult to produce”, Daniel Bojar says.
He hopes the model will constitute a step towards including glycans in approaches to prevent and combat future pandemics, as they are currently neglected in favor of molecules that are simpler to analyze, such as DNA.
“The work of many groups in recent years has really revolutionized glycobiology and I think we are finally at the cusp of using these complex biomolecules for medical purposes. Exciting times are ahead,” says Daniel Bojar.
Title: Using Graph Convolutional Neural Networks to Learn a Representation for Glycans
Publication link: https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00616-1
The researchers have developed graph neural networks for the analysis of glycans. This artificial intelligence technique views a glycan as a graph and learns sequence properties that can be used to predict glycan functions and interactions. The findings have been published in Cell Reports.
Daniel Bojar, assistant professor at the Wallenberg Centre for Molecular and Translational Medicine and the Department of Chemistry and Molecular
Biology, University of Gothenburg.
Phone number: +46 (0)722-099822
Email address: [email protected]
Lost Ark Founders Pack: Everything You Need to Know
Delta Air Lines Flight Diverts To Oklahoma Over Unruly Off-Duty Flight Attendant
Spirit Airlines Just Made The Best Argument For Lifting LaGuardia’s Perimeter Rule
Daiki Axis Co., Ltd. (4245, First Section, Tokyo Stock Exchange) Overview of Operating Performance for the First Three Months Ended March 31, 2021
Clash of Clans June 2021 Update patch notes
Genshin Impact Murals: Location Guide
Africa Leading Bitcoin P2P Trading Volume Growth in 2021
Legends of Runeterra Patch 2.10.0 brings bug fixes and Pool Party cosmetics
DCR Technical Analysis: Look for Support Levels of $130.13 and $126.01
Boeing 727 Set To Be Turned Into Luxury Hotel Experience
Forza Horizon 5 Announced, Launches November 9
Genshin Impact Music Rock Puzzle Guide
In El Salvador’s bitcoin beach town, digital divide slows uptake
Since It Adopted Bitcoin As Legal Tender, The World Is Looking At El Salvador
World of Warcraft 9.1 Release Date: When is it?
Ripple price analysis: Ripple retests $0.80 support, prepares to push higher?
Binance Is Launching a Decentralized NFT Platform
Pre-Owned Luxury Car dealer Luxury Ride to add 80 Employees across functions to boost growth
Jurassic World Evolution 2 Release Date: When is it?
Texas Banks Can Now Provide Bitcoin Custody Services For Clients
Esports1 week ago
Genshin Impact Echoing Conch Locations Guide
Esports1 week ago
All 17 character locations in Collections in Fortnite Chapter 2, season 7
Esports1 week ago
Here are all the milestones in Fortnite Chapter 2, season 7
Esports1 week ago
How to complete Pokémon Go’s A Very Slow Discovery Collection Challenge
Esports1 week ago
Free boxes and skins up for grabs in Brawl Stars to celebrate one-year anniversary of China release
Esports1 week ago
Genshin Impact Kamisato Ayato Speculated for Release
Gaming1 week ago
MUCK: How To Get The Best Weapon | Wyvern Dagger Guide
Esports1 week ago
What Time Does Minecraft 1.17 Release?
AI1 week ago
How to Become a 21st Century Engineer?
Blockchain1 week ago
BPI No Longer Allows Crypto Transactions
Esports1 week ago
How to Fly UFOs in Fortnite
Esports1 week ago
MLB The Show 21 Kitchen Sink 2 Pack: Base Round Revealed